{"id":"unfractionated-heparin-iv","safety":{"commonSideEffects":[{"rate":"1-10","effect":"Bleeding"},{"rate":"0.5-3","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Thrombosis (paradoxical, in HIT)"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unfractionated heparin (UFH) is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically accelerates its inhibition of thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the propagation of existing thrombi. UFH has a rapid onset of action when administered intravenously, making it suitable for acute anticoagulation in time-sensitive clinical scenarios.","oneSentence":"Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:24.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina and myocardial infarction)"},{"name":"Pulmonary embolism treatment and prevention"},{"name":"Deep vein thrombosis treatment and prevention"},{"name":"Atrial fibrillation with thromboembolism risk"},{"name":"Cardiopulmonary bypass anticoagulation"}]},"trialDetails":[{"nctId":"NCT07491393","phase":"PHASE4","title":"Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-04-01","conditions":"Acute Rheumatic Pain","enrollment":24},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT02675647","phase":"PHASE4","title":"Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2015-12","conditions":"Cardiac Surgery, Cardiopulmonary Bypass, Obese Patients (BMI ≥ 30 kg/m²)","enrollment":60},{"nctId":"NCT07015905","phase":"PHASE3","title":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-06-25","conditions":"Venous Thromboembolism (VTE)","enrollment":2000},{"nctId":"NCT05540340","phase":"PHASE1","title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-09","conditions":"Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell","enrollment":39},{"nctId":"NCT06454630","phase":"PHASE2","title":"A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-06-27","conditions":"Venous Thromboembolism","enrollment":179},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT05306899","phase":"PHASE3","title":"Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-06-01","conditions":"Chronic Daily Headache","enrollment":56},{"nctId":"NCT07374978","phase":"NA","title":"Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-01","conditions":"Pulmonary Embolism Subacute Massive, Thrombolytic Therapy","enrollment":100},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07285603","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229","status":"COMPLETED","sponsor":"Matisse Pharmaceuticals","startDate":"2024-11-21","conditions":"Healthy Subjects","enrollment":15},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT05451771","phase":"PHASE1, PHASE2","title":"Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis","status":"RECRUITING","sponsor":"Rajshekhar Chakraborty, MD","startDate":"2022-10-26","conditions":"AL Amyloidosis","enrollment":53},{"nctId":"NCT07005661","phase":"PHASE2, PHASE3","title":"Use of PRP in Open Surgery for Type A Aortic Dissection","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-06-30","conditions":"Aortic Dissection Type A, Transfusions, Platelet Rich Plasma (PRP)","enrollment":250},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":"Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":5},{"nctId":"NCT05284552","phase":"PHASE2","title":"Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","status":"RECRUITING","sponsor":"University Hospital, Linkoeping","startDate":"2022-07-12","conditions":"Epithelial Ovarian Cancer","enrollment":40},{"nctId":"NCT06795698","phase":"PHASE2","title":"The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2019-03-01","conditions":"Fractures, Bone, CKD Stage 4, CKD Stage 3","enrollment":61},{"nctId":"NCT04088292","phase":"PHASE3","title":"Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-06-06","conditions":"Pulmonary Embolism","enrollment":210},{"nctId":"NCT05426031","phase":"PHASE4","title":"Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University of Miami","startDate":"2022-06-28","conditions":"Coagulation; Intravascular","enrollment":130},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT04571645","phase":"PHASE3","title":"Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia","enrollment":9},{"nctId":"NCT05021263","phase":"PHASE3","title":"Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-05-27","conditions":"Colo-rectal Cancer, Anesthesia","enrollment":90},{"nctId":"NCT04794569","phase":"PHASE4","title":"Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-11-15","conditions":"Deep Vein Thrombosis, Post Thrombotic Syndrome","enrollment":9},{"nctId":"NCT02604238","phase":"PHASE3","title":"Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism","status":"WITHDRAWN","sponsor":"Azienda U.S.L. 1 di Massa e Carrara","startDate":"2016-03","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT04409834","phase":"PHASE4","title":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-08-05","conditions":"COVID-19, Venous Thromboembolism, Arterial Thrombosis","enrollment":390},{"nctId":"NCT04261478","phase":"NA","title":"Endovascular Acute Stroke Intervention - Tandem OCclusion Trial","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2020-08-31","conditions":"Stroke, Acute, Carotid Stenosis, Carotid Artery Diseases","enrollment":458},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT02873338","phase":"PHASE2","title":"Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT04725201","phase":"PHASE4","title":"Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization","status":"UNKNOWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-05-24","conditions":"Amputation; Traumatic, Hand","enrollment":188},{"nctId":"NCT04125992","phase":"NA","title":"Distal vs. Forearm Radial Artery Access","status":"COMPLETED","sponsor":"An-Najah National University","startDate":"2019-12-01","conditions":"Coronary Artery Disease, Angina, Unstable, Angina, Stable","enrollment":212},{"nctId":"NCT04072068","phase":"PHASE4","title":"Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy","status":"COMPLETED","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2019-06-27","conditions":"Thromboembolism, Cancer","enrollment":150},{"nctId":"NCT05178550","phase":"EARLY_PHASE1","title":"A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-17","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT05848362","phase":"NA","title":"Comparison of Blood Glucose Measurement Values","status":"UNKNOWN","sponsor":"Uludag University","startDate":"2023-05-17","conditions":"Pain, Acute, Glucose Test Site Bleeding","enrollment":125},{"nctId":"NCT03664180","phase":"PHASE4","title":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-01-11","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":2989},{"nctId":"NCT05742126","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-04-11","conditions":"Healthy","enrollment":54},{"nctId":"NCT03551730","phase":"PHASE2","title":"Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2012-12","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT02056782","phase":"PHASE1","title":"A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2013-12","conditions":"Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT03568838","phase":"PHASE4","title":"Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2018-06-28","conditions":"Myocardial Infarction","enrollment":100},{"nctId":"NCT01743872","phase":"NA","title":"Optical Imaging Measurement of Intravascular Solution Efficacy Trial","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2012-09","conditions":"Peripheral Artery Disease","enrollment":23},{"nctId":"NCT04389840","phase":"PHASE2, PHASE3","title":"Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-07-08","conditions":"Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":27},{"nctId":"NCT01525069","phase":"PHASE1","title":"Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-04-03","conditions":"Cholangiocarcinoma, Liver Neoplasms","enrollment":27},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":"COVID-19 Respiratory Infection, FLU, Cold; Influenza","enrollment":71},{"nctId":"NCT01461915","phase":"PHASE2","title":"Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-11","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT02835534","phase":"PHASE4","title":"The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI","status":"COMPLETED","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2016-05","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":818},{"nctId":"NCT03309137","phase":"NA","title":"Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients","status":"COMPLETED","sponsor":"Alison Fox-Robichaud","startDate":"2017-11-19","conditions":"Infection, Heart; Surgery, Heart, Functional Disturbance as Result, Bacteremia","enrollment":100},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":"COVID-19 Severe Respiratory Failure","enrollment":150},{"nctId":"NCT02501434","phase":"PHASE2","title":"Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin","status":"SUSPENDED","sponsor":"Robert F. James","startDate":"2016-04","conditions":"Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial","enrollment":88},{"nctId":"NCT01161641","phase":"PHASE1","title":"Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2010-07","conditions":"Protein Losing Enteropathy","enrollment":5},{"nctId":"NCT04785885","phase":"","title":"Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery","status":"UNKNOWN","sponsor":"Rhode Island Hospital","startDate":"2021-03-09","conditions":"Transcatheter Aortic Valve Replacement, Cardiac Valve Annuloplasty","enrollment":40},{"nctId":"NCT03079596","phase":"NA","title":"ERAS (Early Recovery After Surgery) Protocol After Laparoscopic Total Gastrectomy and Proximal Gastrectomy","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2019-10-01","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT04274803","phase":"PHASE4","title":"Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?","status":"WITHDRAWN","sponsor":"Tanta University","startDate":"2020-04-01","conditions":"Antiphospholipid Syndrome in Pregnancy","enrollment":""},{"nctId":"NCT04042324","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2019-09-30","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT04533282","phase":"","title":"Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN)","status":"UNKNOWN","sponsor":"Hospital District of Helsinki and Uusimaa","startDate":"2020-11-10","conditions":"Ischemic Heart Disease, Coronary Artery Disease, Aortic Valve Stenosis","enrollment":200},{"nctId":"NCT01346098","phase":"PHASE2","title":"Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2010-07","conditions":"Postpancreatectomy Hyperglycemia","enrollment":60},{"nctId":"NCT02435732","phase":"PHASE1","title":"CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%","status":"UNKNOWN","sponsor":"University of Wisconsin, Madison","startDate":"2020-12","conditions":"Kidney Failure","enrollment":72},{"nctId":"NCT00759083","phase":"PHASE4","title":"Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients","status":"WITHDRAWN","sponsor":"The Medicines Company","startDate":"2008-09","conditions":"Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome","enrollment":""},{"nctId":"NCT00006083","phase":"PHASE3","title":"Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2000-04","conditions":"Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia","enrollment":""},{"nctId":"NCT01839487","phase":"PHASE2","title":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-05-14","conditions":"Metastatic Pancreatic Cancer","enrollment":279},{"nctId":"NCT04435912","phase":"EARLY_PHASE1","title":"Hydrocortisone Per-treatment Decrease Side Effects of Protamine Sulfate","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2019-07-04","conditions":"Blood Pressure, Heart Rate, Airway Pressure","enrollment":200},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT04361526","phase":"NA","title":"Pilot Study on Cytokine Filtration in COVID-19 ARDS","status":"UNKNOWN","sponsor":"Manuel Castellà","startDate":"2020-04-17","conditions":"Coronavirus Infection, Acute Respiratory Distress Syndrome, COVID","enrollment":40},{"nctId":"NCT00854139","phase":"PHASE1","title":"Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2001-08","conditions":"Multiple Myeloma, End Stage Renal Disease","enrollment":10},{"nctId":"NCT00543400","phase":"PHASE2","title":"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Coronary Artery Disease (CAD)","enrollment":503},{"nctId":"NCT02656095","phase":"","title":"Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-03","conditions":"Lipoprotein Lipase Deficiency","enrollment":12},{"nctId":"NCT02739100","phase":"PHASE1","title":"Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2016-04","conditions":"End Stage Renal Disease","enrollment":13},{"nctId":"NCT01433705","phase":"PHASE1","title":"Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-11","conditions":"Heart Disease","enrollment":70},{"nctId":"NCT00073580","phase":"PHASE3","title":"Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-10","conditions":"Thrombocytopenia, Thrombosis, Cardiac Disease","enrollment":88},{"nctId":"NCT02554032","phase":"NA","title":"The Aortic Surgery Cerebral Protection Evaluation (ACE) Randomized CardioLink-3 Trial","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2015-06","conditions":"Aortic Aneurysm, Thoracic","enrollment":110},{"nctId":"NCT00331162","phase":"PHASE4","title":"Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-02","conditions":"Graft Rejection","enrollment":222},{"nctId":"NCT01058759","phase":"PHASE3","title":"Taxotere-Enoxaparin-(ENOXA)-Study","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2009-11","conditions":"Non-small Cell Lung Cancer","enrollment":14},{"nctId":"NCT00800137","phase":"PHASE4","title":"Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2008-12","conditions":"Hematoma","enrollment":984},{"nctId":"NCT02100228","phase":"PHASE4","title":"Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07-14","conditions":"Atrial Fibrillation","enrollment":1500},{"nctId":"NCT01520454","phase":"NA","title":"Effect of Increased Free Fatty Acids on Leptin Function","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2011-11","conditions":"Obesity, Leptin Resistance","enrollment":26},{"nctId":"NCT03483207","phase":"NA","title":"Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-04-01","conditions":"Mesenteric Vein Thrombosis","enrollment":30},{"nctId":"NCT02271113","phase":"PHASE1","title":"Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlycoMimetics Incorporated","startDate":"2014-10","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT02164097","phase":"PHASE1","title":"ODSH + ICE Chemotherapy in Pediatric Solid Tumors","status":"TERMINATED","sponsor":"New York Medical College","startDate":"2015-01","conditions":"Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma","enrollment":4},{"nctId":"NCT02681016","phase":"NA","title":"Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2015-03","conditions":"Ischemic Heart Disease, Coronary Atherosclerosis, Coronary Artery Disease","enrollment":610},{"nctId":"NCT00433966","phase":"PHASE3","title":"Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Cardiovascular Research Foundation, New York","startDate":"2005-03","conditions":"Myocardial Infarction","enrollment":3602},{"nctId":"NCT02966080","phase":"NA","title":"Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"2016-12","conditions":"Acute Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Bleeding","enrollment":""},{"nctId":"NCT01042704","phase":"PHASE1","title":"Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Robert Redner, MD","startDate":"2008-02","conditions":"Myeloma","enrollment":29},{"nctId":"NCT02722720","phase":"NA","title":"Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2015-09","conditions":"Carotid Atherosclerosis, Carotid Stenosis, Ischemic Attack","enrollment":200},{"nctId":"NCT01913483","phase":"PHASE3","title":"ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2013-09-24","conditions":"Peripheral Endovascular Interventions, Bleeding","enrollment":732},{"nctId":"NCT02707263","phase":"NA","title":"Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-03","conditions":"Venous Thromboembolism","enrollment":""},{"nctId":"NCT01651780","phase":"PHASE3","title":"Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2012-10","conditions":"Severe Aortic Stenosis, Transcatheter Aortic Valve Replacement, Aortic Valve Replacement","enrollment":803},{"nctId":"NCT01938313","phase":"PHASE2","title":"Early Recovery After Surgery (ERAS) Versus Conventional Protocol After Laparoscopic Gastrectomy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2012-08","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT02590471","phase":"PHASE4","title":"Pilot Prospective Study of Two Methods of Revascularization of the Femoral Artery (SFA): Stenting in the SFA, and Stenting of the SFA, Supplemented by Fasciotomy in Hunter Channel.","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2015-10","conditions":"Atherosclerosis of the Peripheral Artery","enrollment":50},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092},{"nctId":"NCT00003674","phase":"PHASE3","title":"Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1998-12","conditions":"Breast Cancer, Colorectal Cancer, Lung Cancer","enrollment":141},{"nctId":"NCT02769650","phase":"NA","title":"Stress-MRI Assessment After Right Coronary Artery CTO Recanalization","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2010-10","conditions":"Ischemic Heart Disease, Coronary Atherosclerosis, Coronary Artery Disease","enrollment":72},{"nctId":"NCT02708329","phase":"NA","title":"T-provisional Stenting vs Mini-Crush in Chronic Total Occlusions (CTO)","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2011-01","conditions":"Ischemic Heart Disease, Coronary Atherosclerosis, Coronary Artery Disease","enrollment":146},{"nctId":"NCT01076764","phase":"PHASE3","title":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Acute Coronary Syndrome","enrollment":13220},{"nctId":"NCT00351663","phase":"PHASE4","title":"The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2007-02","conditions":"Venous Thrombosis, Critical Illness","enrollment":39},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT00031837","phase":"PHASE3","title":"Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Gary Morrow","startDate":"2002-10","conditions":"Pancreatic Cancer, Thromboembolism","enrollment":400},{"nctId":"NCT02529774","phase":"PHASE2, PHASE3","title":"Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Ye Xu","startDate":"2015-09","conditions":"Resected Liver Metastases From Colorectal Cancer","enrollment":432},{"nctId":"NCT01547728","phase":"PHASE4","title":"Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2012-02","conditions":"Thrombophilia Due to Acquired Antithrombin III Deficiency","enrollment":42},{"nctId":"NCT02497326","phase":"NA","title":"Heparin for the Treatment of Burn Wound Pain","status":"UNKNOWN","sponsor":"King Edward Medical University","startDate":"2015-04","conditions":"Second Degree Burns","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"HAEMATOMA MUSCLE"},{"count":1,"reaction":"HYPOTENSION"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Unfractionated Heparin IV","genericName":"Unfractionated Heparin IV","companyName":"The TIMI Study Group","companyId":"the-timi-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors. Used for Acute coronary syndrome (unstable angina and myocardial infarction), Pulmonary embolism treatment and prevention, Deep vein thrombosis treatment and prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}